■ Vivavision Biotech Ltd. announced positive results of a phase 2 study to assess the safety and efficacy of VVN539 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension. Investigators evaluated 2 concentrations of (0.04% and 0.02%) and assessed ocular and systemic safety.

VVN539 acts directly on the trabecular meshwork, increasing the outflow of aqueous humor. In a preclinical animal model, VVN539 exhibited “remarkable IOP lowering efficacy, and this innovative drug is expected to be competitive in the global glaucoma market,” according to a news release.

The 0.04% VVN539 concentration was statistically superior to vehicle at all 9 diurnal time points over the course of the 21 days study, with a decrease from unmedicated baseline of 5 mmHg to 6 mmHg. The 0.02% concentration provided statistically significant decreases from unmedicated baseline relative to its vehicle at a majority of time points. The agent appears safe and well tolerated, according to a news release. Further clinical studies of the drug will explore the therapeutic potential in comparison with a first-line hypotensive drug in a lager patient population, the company added.